| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA677: Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma |
|
Medicine details |
|
| Medicine name | Autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel [Tecartus®]) |
| Formulation | Solution for infusion |
| Reference number | 4795 |
| Indication | Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor
|
| Company | Gilead Sciences Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 21/01/2021 |
| NICE guidance | |